Medical Device News Magazine

Dr. Woodrow Myers Joins the Freespira Board of Directors

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Freespira, Inc., maker of the first FDA-cleared digital therapeutic to significantly reduce or eliminate symptoms of panic attacks, panic disorder and post-traumatic stress disorder (PTSD) in only 28 days, today announced that Woodrow (Woody) Myers, MD, has joined the company’s Board of Directors.

Dr. Woodrow Myers is a nationally recognized leader in the development of healthcare quality initiatives and advanced healthcare management programs. He has over 40 years’ experience as a physician and clinical and business leader at some of the industry’s largest and most prestigious healthcare enterprises. In his current role, as managing director of Myers Ventures LLC, he has served as chief medical officer and chief healthcare strategist for Blue Cross Blue Shield of Arizona, CEO for Valitàs Health Services (Corizon Health), and a consultant to the $3 billion California Endowment, that state’s largest private health foundation.

“Freespira’s breakthrough treatment for panic disorder and PTSD epitomizes the critical importance of innovation in healthcare – and the power of human-centered  technology to make a difference in the lives of those who struggle with debilitating mental illnesses on a daily basis,” said Dr. Myers. “I’m excited to join Freespira’s Board of Directors to help the company continue to expand its already strong reach. Together, we can serve more of the millions of Americans who are suffering and desperately need access to new life-changing therapies.”

Freespira CEO Dean Sawyer commented, “We’re honored that Dr. Myers is joining our Board of Directors. Throughout his impressive career, he has proven to be deeply committed to improving healthcare by embracing innovation and technology, especially to support our nation’s underserved populations who deserve far better access to far better care. Most importantly, Dr. Myers brings not only invaluable knowledge and experience to the Board but also a strong passion for our mission of helping people to lead happier, healthier, symptom-free lives.”

Dr. Myers previously served as the executive vice president and chief medical officer of WellPoint, Inc., where he established the Healthcare Quality Assurance Division. Prior to that, he served as the director of healthcare management at the Ford Motor Company where he initiated quality assurance metrics for Ford healthcare vendors and established new global health and safety policies. Prior to Ford, he was corporate medical director for The Associated Group (now Anthem Blue Cross Blue Shield). He is also a former health commissioner for New York City and the state of Indiana.

He earned his medical degree (MD) from Harvard University, and a Master of Business Administration (MBA) from Stanford University. Early in his medical career he worked as an emergency room physician and as a critical care intensivist and in both roles as a clinical teacher.

The Freespira Board of Directors now includes the following members in addition to Dr. Myers and Mr. Sawyer: Executive chairman Russ Siegelman, a former Kleiner Perkins leader and current Stanford Business School lecturer; Ned Scheetz, founder and managing partner of Aphelion Capital; Jonathan MacQuitty, venture partner at Lightspeed Venture Partners; Steve Schwartz, executive vice president of mergers and acquisitions for Senior Connect Acquisition Corp.; and Debra Reisenthel, founding CEO of Freespira.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”